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Kajian tentang aktiviti terbitan isoniazid dan gabungannya dengan drug        
anti-tibi yang lain ke atas Mycobacterium tuberculosis  
 
ABSTRAK 
Sel membran yang kurang telap terhadap drug anti-tibi yand berciri hidrofilik 
terutamanya isoniazid (INH), merupakan salah satu faktor penting yang 
menyumbang kepada ketahanan intrinsik dalam Mycobacterium tuberculosis. 
Banyak kajian menghipotesiskan bahawa aktiviti anti-mikobakteria bagi INH dapat 
ditingkatkan dengan menjadikannya sebatian hidrofobik/lipofilik. Berasaskan 
hipotesis ini 13 terbitan yang berbeza hidrofobisitinya disintesis melalui penambahan 
rantai asil hidrofobik kepada INH. Kajian ini bertujuan untuk mengkaji aktiviti    
anti-tibi terbitan-terbitan tersebut dan saling tindak mereka dengan drug-drug      
anti-tibi yang lain seperti INH, streptomisin (STR), rifampisin (RIF), dan etambutol 
(EMB). Kajian ini juga bertujuan mengkaji aktiviti terbitan INH yang berpotensi 
terhadap kehidupan M. tuberculosis H37Rv dan perubahan morphologi sel pada fasa 
kitaran hidup yang berlainan. Morfologi sel M. tuberculosis H37Rv ATCC 25618 
semasa kitaran pertumbuhan didapati lebih baik dikaji menggunakan medium agar 
kerana peringkat pertumbuhan dalam medium ini lebih jelas lagi berbanding dengan 
medium cecair. Aktiviti anti-tibi terbitan-terbitan ini telah dikaji dengan menentukan 
kepekatan perencatan minimum (MIC) terhadap M. tuberculosis H37Rv 
menggunakan “tetrazolium microplate assay” (TEMA). Antara terbitan yang diuji,  
1-isonikotinoil-2-heksadekanoil hidrazina (INH-C16),                                               
1-isonikotinoil-2-heptadekanoil hidrazina (INH-C17) dan                                           
1-isonikotinoil-2-oktadekanoil hidrazina (INH-C18) mempunyai nilai MIC dua kali 
ganda lebih rendah daripada INH. Justeru itu, saling tindak terbitan-terbitan tersebut 
xv 
 
dengan drug anti-tibi yang lain telah dikaji menggunakan kaedah “fixed-ratio 
isobologram”. INH-C16 menunjukkan saling tindak yang sangat baik dengan STR 
dan RIF. Berdasarkan penemuan ini, INH-C16 telah dipilih untuk kajian selanjutnya 
ke atas sel. Keputusan yang diperolehi menunjukkan bahawa M. tuberculosis sangat 
sensitif terhadap INH-C16 pada fasa permulaan, logaritma dan kematian dalam 
kitaran hidupnya. Pemerhatian di bawah mikroskop cahaya menunjukkan bahawa 
sel-sel yang dirawat dengan INH-C16 cenderung untuk membentuk kelompok dan 
hilang sifat ketahanan asid pada fasa permulaan, logaritma dan pegun. Sel-sel yang 
dirawat kemudian dilihat di bawah mikroskop elektron penskanan dan transmisi. 
INH-C16 menyebabkan dinding sel pecah lalu menyebabkan kehilangan integriti sel 
justeru menyebabkan sel-sel lisis dan mati. Pemerhatian ini mencadangkan bahawa 
mekanisma tindakan INH-C16 mungkin melalui perencatan sintesis asid mikolik. 
Maka, ia boleh disimpulkan bahawa INH-C16 mempunyai potensi untuk 
penyelidikan selanjutnya sebagai drug anti-tibi. 
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Studies on the activity of isoniazid derivatives and their combinations with other 
anti-TB drugs on Mycobacterium tuberculosis 
 
ABSTRACT 
The low permeability of the cell envelope against hydrophilic anti-tuberculosis (TB) 
drugs especially isoniazid (INH), is one of the crucial factors that contribute to the 
intrinsic resistance in Mycobacterium tuberculosis. Previous studies have floated the 
idea that the anti-mycobacterial activity of INH can be enhanced by augmenting the 
hydrophilic INH into a hydrophobic/lipophilic compound. Therefore, a series of 13 
derivatives with different hydrophobicity were synthesized by adding different 
hydrophobic acyl chain to the parent compound, INH. The current study was aimed 
to investigate the anti-TB activity of these derivatives and their interactions with the 
first-line anti-TB drugs such as INH, streptomycin (STR), rifampicin (RIF) and 
ethambutol (EMB). The study was also aimed to elucidate the activity of potential 
hydrophobic INH derivative on the viability of M. tuberculosis H37Rv at the cellular 
level at different phases of the growth cycle. The cellular morphology of                 
M. tuberculosis H37Rv ATCC 25618 during the growth cycle was best studied using 
solid medium as the growth stages were well defined compared to the liquid 
medium. The anti-TB activity of these derivatives was carried out by determining the 
minimum inhibitory concentration (MIC) against M. tuberculosis H37Rv using a 
tetrazolium microplate assay (TEMA). Among the derivatives tested,                        
1-isonicotinoyl-2-hexadecanoyl hydrazine (INH-C16),                                               
1-isonicotinoyl-2-heptadecanoyl hydrazine (INH-C17) and                                               
1-isonicotinoyl-2-octadecanoyl hydrazine (INH-C18) were shown to have two-fold 
lower MIC value than INH. Their interactions with first-line anti-TB drugs were then 
xvii 
 
performed using a fixed-ratio isobologram method. INH-C16 showed most 
promising interaction with STR and RIF. Based on these findings, INH-C16 was 
selected for further studies on the cells. The results obtained indicated that              
M. tuberculosis H37Rv was most susceptible to INH-C16 at the lag, log and death 
phase of the growth cycle. Observation under light microscope indicated that      
INH-C16 treated cells tend to form clumps and lost their acid-fastness properties at 
lag, log and stationary phase. The treated cells were further viewed under scanning 
and transmission electron microscope. INH-C16 caused the cell wall to rupture that 
made the cells to lose their cellular integrity and ultimately led to cell lysis and death. 
These observations suggest that the action mechanism of INH-C16 could be via the 
inhibition of mycolic acid synthesis. Hence, it could be concluded that INH-C16 has 
the potential to be a drug lead worthy of further investigations.  
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SECTION 1 
INTRODUCTION 
 
1.1 PROBLEM STATEMENT 
Mycobacterium tuberculosis is a resilient human pathogen which causes 
tuberculosis (TB). According to the World Health Organization (WHO), there were 
8.8 million TB cases in 2010 globally (WHO, 2011b). During the same year, a total 
of 1.45 million people died of the disease, of which, 0.35 million were human 
immuno-deficiency virus (HIV) positive patients. Moreover, the emergence of 
multidrug resistant TB (MDR-TB) and extremely drug resistant TB (XDR-TB) 
render the control of TB even more difficult. In 2008, around 390 000 - 510 000 
MDR-TB incidence cases were reported worldwide with 150 000 deaths (WHO, 
2010c). In Malaysia, it was reported that the incidence rate of TB was around 63.95 
cases per 100 000 population and the mortality rate was 5.49 death per 100 000 
population in 2008 (Ministry of Health Malaysia, 2009). Apparently, TB had caused 
more death than any other communicable infectious diseases such as dengue, hand, 
food, and mouth diseases etc. This suggests that urgent attention should be given to 
circumvent this harrowing phenomenon.  
The modern, standard short-course therapy for TB recommended by WHO is 
based on a combination of at least three first-line anti-TB drugs regimen that relies 
on direct observation of patient compliance to ensure effective treatment (WHO, 
2003).
 
TB patients receive combination therapy instead of mono therapy because the 
latter can also delay the emergence of drug resistant M. tuberculosis strains and 
reduce the resistant effects to existing drugs (Cynamon, 2001). While TB is curable, 
MDR-TB may be fatal and the management of MDR-TB is more complicated, 
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costlier, and needs highly skilled medical personnel (da Silva and Aínsa, 2007).     
MDR-TB also demands treatment with second-line drugs that are often less effective, 
more toxic and expensive. Hence, the urgent need to develop new drugs which are 
more effective, less toxic and cheaper than the present anti-TB agents cannot be 
overemphasized.  
Among the first-line anti-TB agents, isoniazid (INH) is the most prominent 
drug which is exquisitely potent with a minimum inhibitory concentration (MIC) 
ranging from 0.02 to 0.2 µg/mL (Makarov et al., 2009).
 
However, in the last decade, 
the number of INH resistant M. tuberculosis strains isolated from TB patients had 
been increasing at an alarming rate (WHO, 2010b).
 
One of the intrinsic factors 
contributing to INH resistance in M. tuberculosis is the underlying architecture of the 
bacterial cell envelope (Rastogi et al., 1981, Rastogi et al., 1986, Rastogi and Goh, 
1990, Jarlier and Nikaido, 1994, Brennan and Nikaido, 1995).
 
Unlike other bacteria, 
the cell wall of M. tuberculosis is double-layered, comprising of an inner       
electron-dense layer of peptidoglycan and an outer electron-transparent layer 
containing mycolyl arabinogalactan complex covalently bound to the peptidoglycan 
(Takade et al., 2003, Dahl, 2004).
 
The outer layer of M. tuberculosis functions as an 
exclusion barrier towards hydrophilic drugs, such as INH (Rastogi and Goh, 1990, 
Brennan, 2003).
 
As a hydrophilic compound, INH molecules diffuse into the bacteria 
via the protein channel known as porin (Liu et al., 1999). This penetration via 
mycobacterial porin had been shown to be very slow because it is inefficient in 
allowing the permeation of solutes and also exists in low concentration (Faller et al., 
2004).
 
Thus, the cell wall structure and INH penetration through the lipid domain 
provide opportunities for rational anti-TB drug design strategies focused on drug 
lipophilicity.  
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Previous studies have emphasized that chemical modifications of INH by 
increasing its lipophilic property resulted in enhanced activity of INH against          
M. tuberculosis (Rastogi and Goh, 1990, Bardou et al., 1996, Billington et al., 1998, 
De Logu et al., 2002). A study by Mohamad et al. (2004) also reported that a 
lipophilic INH derivative, 1-isonicotinyl-2-nonanoyl hydrazine (INH-C9) had a 
lower MIC value compared to INH. Furthermore, this observation was also 
supported by molecular modelling study that INH derivatives with longer acyl chain 
have greater binding affinity to InhA enzyme which plays a crucial function in 
mycolic acid biosynthesis in M. tuberculosis cell wall (Qamar, 2004).
 
On the basis of 
these antecedents, the major objectives of the current study is to further prove and 
validate the hypothesis that the anti-TB activity of INH could be enhanced by 
augmenting it into a hydrophobic compound. In addition, the interaction between the 
potential derivatives and common first-line anti-TB drugs was also studied. Finally, 
the effects of the potential lipophilic derivative on M. tuberculosis H37Rv cells at the 
cellular level were also observed.
 
 
1.2 GENUS MYCOBACTERIUM 
Genus Mycobacterium is classified as an ancient genus  because it is assumed 
that this genus was originated more than 150 million years ago (John, 1984). 
Theoretically, the name “myco” which means fungus was given by their special 
characteristic to exhibit filamentous growth in liquid medium (Tortora et al., 1989).  
The taxonomy lineage of genus Mycobacterium is shown in Figure 1.1. The 
prominent member of this genus is Mycobacterium tuberculosis which is an obligate 
human pathogen (Saviola and Bishai, 2006). Its variants or subtypes Mycobacterium 
africanum and Mycobacterium canetti are also pathogenic to human. Mycobacterium 
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bovis and Mycobacterium microti cause TB in animals and can be transmitted to 
humans (Barrera, 2007). Mycobacterium caprae and Mycobacterium pinnipedii were 
isolated and identified from TB-infected goats and seals (Barrera, 2007). 
 
Kingdom 
Phylum 
Class 
Subclass  
Order 
Suborder 
Family 
Genus 
Species 
Bacteria 
Actinobacteria 
Actinobacteria 
Actinobacteridae 
Actinomycetales 
Corynebacterineae 
Mycobacteriaceae 
Mycobacterium 
M. tuberculosis 
M. africanum 
M. microti 
M. canetti 
M. caprae 
M. bovis 
M. pinnipedii 
 
Figure 1.1   Taxonomy lineages of TB agents (Source : Barrera, 2007)  
 
Bacteria from this genus are Gram-positive, aerobic, non-motile,               
non-sporulate, and long, slender, straight, or curved rod-shaped with a slight 
tendency to be filamentous or branching (Tortora et al., 1989, Saviola and Bishai, 
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2006, Barrera, 2007, Talaro, 2008). These microorganisms also show a unique 
staining characteristic known as an acid-fastness property (Madigan and Martinko, 
2006). This characteristic is due to high lipid content in their cell wall, probably the 
highest among all the bacteria. This lipid is known as mycolic acid (Saviola and 
Bishai, 2006, Talaro, 2008). The mycolic acid content imparts to cell wall 
hydrophobicity which renders immunological properties, resistance against wide 
range of antimicrobial agents and to injuries, and also contributes to the slow growth 
rate in some of mycobacterial species (Barrera, 2007).  
Generally, this genus can also be further divided into fast growers and slow 
growers. The mycobacteria are categorized as fast growers if they are able to form 
visible colonies on selective media in less than 7 days, whereas slow growers take 
more than 7 days (Saviola and Bishai, 2006). Table 1.1 shows the list of fast growers 
and slow growers of the genus Mycobacterium.   
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Table 1.1 List of fast growers and slow growers of the genus Mycobacterium 
 
Fast growing Mycobacterium Slow growing Mycobacterium 
M. fortuitom 
M. farginogenes 
M. senegalense 
M. chelorne 
M. penegrum 
M. neaurum 
M. diernhoferi 
M. abscessus 
M. chitae 
M. fullax 
M. aurum 
M. vaccae 
M. confluentis 
M. madagascariense 
M. flavescens 
M. smegmatis 
M. thermoresistible 
M. phlei 
 
 
M. triviaic 
M. simae 
M. genavense 
M. interjectum 
M. intermedium 
M. terrar 
M. hibernine 
M. nonchromogenicum 
M. cookii 
M. xenopi 
M. celatum 
M. gordonae 
M. asiaticam 
M. tuberculosis complex 
M. marinum 
M. leprae 
M. scrofmlaceni 
M. gratrif 
M. kansasii 
M. szugni 
M. malmacuse 
M. intracellulars 
M. paratuberculosis 
M. avium 
 
(Source : Saviola and Bishai, 2006)   
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Mycobacteria can also be grouped based on their ability to form yellow, 
orange, or pink carotenoid pigments (Madigan and Martinko, 2006, Talaro, 2008). 
The pigmentation can be photochromogenesis (forming pigment only when cultured 
in the light, such as M. kansasii and M. marinum), scotochromogenesis (forming 
pigment when cultured in the dark for example M. gordonae), or  nonpigmented 
(such as M. tuberculosis and M. bovis) (Madigan and Martinko, 2006).  
Occasionally, the members of this genus are clustered into complexes based 
on genetic similarities, similar disease syndrome and identical 16S ribosomal 
ribonucleic acid (RNA) gene sequence (Gillespie, 2006), such as Mycobacterium 
tuberculosis complex and Mycobacterium avium complex. M. tuberculosis complex 
comprises of human pathogenic microorganisms such as M. tuberculosis, M. bovis, 
M. microti, M. africanum, M. caprae, and M. pinnipedii (Saviola and Bishai, 2006, 
Barrera, 2007). The members of this complex are also known as “tubercle bacilli” 
(Collins et al., 1984). Meanwhile, M. avium complex is composed of M. avium and 
M. intracellulare which can cause opportunistic and disseminated infection in AIDS 
patients (Inderlied et al., 1993). 
 Thus, it can be concluded that the genus Mycobacterium is medically pivotal 
because this genus consists of a number of human pathogenic species of bacteria that 
can cause severe diseases in human which may lead to fatality. 
 
1.3 MYCOBACTERIUM TUBERCULOSIS 
1.3.1 Classification  
M. tuberculosis is a well-studied and medically most important member of 
the M. tuberculosis complex (Collins et al., 1984). It is a nonpigmented, obligate 
human pathogen and very seldom identified in other mammals (Madigan and 
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Martinko, 2006, Saviola and Bishai, 2006). It does not have a significant 
environmental reservoir and it is only transmitted from person to person (Saviola and 
Bishai, 2006).  
The genomic studies of M. tuberculosis H37Rv revealed that it consisted of   
4 411 529 base pairs with very high guanine plus cytosine (G + C) content and 4 000 
genes (Cole et al., 1998). The study also highlighted that large portion of the genes 
were coded for; (1) production of enzymes involved in lipogenesis and lipolysis 
which makes the M. tuberculosis differ radically from other bacteria and,                
(2) glycine-rich proteins with a repetitive structure that functions as a source of 
antigenic variation of M. tuberculosis H37Rv (Cole et al., 1998). 
 
1.3.2 Microscopic morphology  
Microscopically, the tubercle bacilli are observed as straight or slightly 
curved rods. The bacilli are 1 - 10 µm in length (usually 3 - 5 µm) and 0.2 - 0.6 µm 
in width (Barrera, 2007). The bacilli also exhibit heterogeneity population where the 
cells may be different in sizes and shapes (from coccobacilli to long rods) that 
depends on the growth condition and age of the culture (Barrera, 2007, Thanky et al., 
2007). Thanky et al. (2007) reported that extensive heterogeneity occurred during the 
exponential phase of the growth cycle where the cells were actively participating in 
cell division and elongation process at this time. They elucidated that as the cells 
enter the stationary phase, the cells become shorter due to reduction of nutrient in the 
culture. This causes biosynthetic processes to slow down in the older culture that 
leads to a mixture of cells.  
It has also been reported that the actively multiplying bacilli are strongly 
acid-fast and tend to form hydrophobic bundles known as serpentine cord formation 
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(Barrera, 2007). The serpentine cord formation is defined as rope-like aggregates of 
bacterial cells in position parallel to the long axis of the cord as shown is Figure 1.2. 
  
 
 
Figure 1.2   Microscopic morphology of M. tuberculosis growth exhibiting 
serpentine cording (Source: Attori et al., 2000). 
 
The cord formation is often associated with virulence of M. tuberculosis 
because this characteristic was found to be very specific (97.3 to 99.5 %) for           
M. tuberculosis (Yagupsky et al., 1990). Several studies had reported that this 
morphology could be used as a presumptive identification tool to differentiate 
between M. tuberculosis and other mycobacterial species (Yagupsky et al., 1990, 
Morris and Reller, 1993, González et al., 1998, Attorri et al., 2000, Tu et al., 2003). 
In a related study, Noll et al. (1956) showed that this distinctive microscopic 
morphology of tubercle cells are attributed to trehalose 6, 6’-dimycolate (TDM) 
which is an extractable glycolipid made of two mycolic acid molecules and one 
molecule of disaccharide trehalose which are loosely bound in the outer layer of the 
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cell wall. It had been reported that this glycolipid displays usual toxicity and 
virulence factors of M. tuberculosis (Behling et al., 1993) as well as contributing to 
the innate macrophage response during M. tuberculosis infection (Indrigo et al., 
2002). Moreover, the TDM composition also differs among the strains of 
mycobacterium due to the difference in the mycolic acid moieties between the strains 
(Behling et al., 1993).  
  
1.3.3 Colony morphology 
Mycobacterium strains are known to behave differently in regard to their 
gross colonial morphology, the medium and their pathogenicity. For instance,      
Will et al. (1951) reported that on egg medium, virulent tubercle bacilli produce a 
dry waxy friable colony that crumbles when rubbed with inoculum loops while, 
avirulent cells produce firm compact colonies that do not crumble and easily 
emulsify in fluid. They also reported that on sodium oleate agar both virulent and 
avirulent colonies were wrinkled, flat, spreaded, and corded. On the other hand, the 
colonies were cream-coloured, buff and rough on the Lowenstein-Jensen (LJ) 
medium (WHO, 1998, Monteiro et al., 2003). Several studies suggested that these 
various colonial morphologies are due to the presence of a class of surface antigens 
so called lipids (Fregnan et al., 1962), glycopeptidolipids (Barrow and Brennan, 
1982) or lipooligosaccharides (McNeil et al., 1989).  
 
1.3.4 Growth  
Under favorable laboratory conditions, the generation time of M. tuberculosis 
is 18 to 24 hours on stationary cultures and 10 to 12 hours on shake cultures 
(Harshey and Ramakrishnan, 1977). The clinical specimens were often at lag phase 
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for three to four weeks before sufficient growth is observed (Saviola and Bishai, 
2006). This is extremely slow compared to other cultivable bacteria. Hence, this 
explains the need for a longer time of incubation to acquire visible colonies in vitro.  
Eventually, this also makes early detection of the disease cumbersome.  
The most commonly used mediums for growth assessment of M. tuberculosis 
are egg-based medium (e.g. LJ medium) and agar-based medium (e.g. Middlebrook 
7H10 and Middlebrook 7H11 supplemented with glycerol and enriched with oleic 
acid, albumin, dextrose, and catalase (OADC)) as well as liquid medium such as 
Middlebrook 7H9 supplemented with glycerol and enriched with albumin, dextrose 
and catalase (ADC) (Saviola and Bishai, 2006). These media contain a variety of 
inorganic salts which provide necessary nutrients for the healthy growth of 
mycobacteria. In addition, these media also contain malachite green to reduce 
contamination by partially inhibiting other normal floral bacteria. The enrichment 
media contain albumin which endow protection against toxic agents and therefore, 
enhances the growth of mycobacterial cells (Middlebrook, 2010). 
The growth of M. tuberculosis cells is also highly dependent on the physical 
condition of the environment such as temperature, pH, oxygen concentration, and 
salinity. In general, M. tuberculosis is a mesophile (organism that shows optimum 
growth at temperature ranging from 25 to 40
 
°C) and neutrophile (organism that 
grows best around pH 7) (Madigan and Martinko, 2006, Barrera, 2007). The cells 
also require oxygen as a final electron acceptor in aerobic respiration. So, the 
tubercle cells grow most successfully in the tissues rich with oxygen such as in the 
lungs especially at the well-aerated upper lobes (Barrera, 2007). It is hypothesized 
that at the lowest oxygen condition the tubercle cells enter the stationary phase and 
become dormant (Wayne, 1982). A research by Wayne and Lin (1982) showed that 
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when the M. tuberculosis cells were grown in liquid medium without agitation, they 
adapted to microaerophilic condition (oxygen at a level lower than that in the air) in 
the sediment and the cells at this sediment did not replicate but were tolerant of 
anaerobiosis. Hence, this implies that low oxygen concentration plays an important 
role in mycobacterial dormancy and adaptation to anaerobiosis which perhaps would 
be a feature of persisting tubercle bacilli (Cunningham and Spreadbury, 1998). 
Cunningham and Spreadbury (1998) also showed that the tubercle bacilli adapt to 
low oxygen conditions by developing a thickened cell wall and expression of a 
unique 16 kilo Dalton protein which confers an advantage to the bacilli during its 
dormant phase by stabilizing as well as protecting cell structures. 
Even though tubercle bacilli grow best at the optimum condition as 
mentioned earlier, yet it can still withstand condition quite extreme from those 
environments. For instance, the tubercle bacilli can survive in the mild acidic and 
alkaline microenvironment. This is because in in vivo environment, the cells 
encounter an acidic environment in the lungs, stomach and macrophage phagosome 
yet, the cells are able to survive (Cotter and Hill, 2003). Based on this idea, sodium 
hydroxide, an alkaline solution was used to decontaminate clinical specimens of TB 
which inactivates the contaminating microfloral bacteria in the sample with only 
modest inhibitory effects against mycobacteria (Saviola and Bishai, 2006). Besides, 
the cells can also withstand very low temperature seeing that the stock culture can be 
preserved at temperature as low as -70 °C for 2.5 to 5 years (Kim and Kubica, 1972, 
Kim and Kubica, 1973, Kubica et al., 1977). Researchers also found that the cells 
frozen at this temperature have 100 % viable bacterial suspension, metabolic 
activities were stable, inoculums was highly reproducible for animal experiments, 
genetic constituents were maintained, as well as with minimal clonal selection of 
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undesirable mutants (Kim and Kubica, 1972, Kim and Kubica, 1973, Kubica et al., 
1977). 
 
1.3.5 Cell wall: structure and permeability 
Structure: Figure 1.3 represents the structure of mycobacterial cell envelope. Unlike 
other bacteria, the cell envelope of M. tuberculosis consists of three main sections: 
plasma membrane, cell wall and outer capsule like layer (Crick et al., 2001, Barrera, 
2007). The uniqueness of the cell envelope of M. tuberculosis solely relies on its cell 
wall architecture as it plays a prominent role in the pathogenicity of the disease (as 
discussed in Section 1.3.7), immunological reactions of host to mycobacteria and 
gives the cells acid-fastness characteristics (Barksdale and Kim, 1977, Liu et al., 
1999). In addition, many work have also highlighted that the architecture of the cell 
wall is one of the intrinsic factors that contributes to the drug resistance in               
M. tuberculosis (Rastogi and Goh, 1990, Lisowska et al., 1996, Chatterjee, 1997, Liu 
et al., 1999, Brennan, 2003, Barkan et al., 2009).  
Studies have shown that the cell wall of mycobacteria is composed of three 
covalently linked major core compounds; 
Peptidoglycan: It functions as a backbone of cell wall and protects the 
microorganism from degradation and is made of alternating units of                             
N-acetylglucosamine and N-glycolyl muramic acid (Chatterjee, 1997, Crick et al., 
2001, Alderwick et al., 2007),  
Arabinogalactan: It comprised of arabinan and galactan where the arabinan 
constitutes of branched pentaarabinofuranosyl and galactan consists of 5- and          
6-linked galactofuranose (Chatterjee, 1997, Crick et al., 2001, Alderwick et al., 
2007), and 
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Mycolic acid: It is an exquisitely long (up to 90 carbon atoms) α-branched and        
β-hydroxylated fatty acids and it consists of one-third dry mass of the cell wall 
(Faller et al., 2004). It is undeniable that mycolic acid is a biologically important 
component that plays a vital role in viability and cell wall structure (Barkan et al., 
2009). It is also involved in the formation of trehalose dimycolate (which is known 
as cord factor which implicates the pathogenesis of M. tuberculosis) and trehalose 
monomycolate (acts as a precursor for arabinan-linked mycolates) (Chatterjee, 1997, 
Jackson et al., 2007).  
In brief, the arabinogalactan chains covalently bond to cross-linked 
peptidoglycan via phosphoryl-N-acetylglucosaminosyl-rhamnosyl linkage units and 
then the arabinogalactan in turn is esterified to α-alkyl, β-hydroxy mycolic acids 
(Crick et al., 2001, Alderwick et al., 2007).  
On the other hand, observation under transmission electron microscopy 
(TEM) revealed that the cell wall contains two distinct layers;   
(1) An inner electron-dense layer of peptidoglycan (Paul and Beveridge, 
1992, Takade et al., 2003, Dahl, 2004). The thickness, electron density and 
appearance of this layer varied depending on the species, growth conditions and 
methods of preparation for microscopy (Liu et al., 1999).  
(2) An outer electron-transparent layer containing mycolyl 
arabinogalactan complex covalently bound to the peptidoglycan (Paul and 
Beveridge, 1992, Takade et al., 2003, Dahl, 2004). This layer appears to be 
extremely hydrophobic in nature due to the mycolyl arabinogalactan (Liu et al., 
1999). Hence, it is hypothesized that the outer layer could hinder the diffusion of 
chemotherapeutic agents across the cell wall thus causing drug resistance by 
exclusion barrier (Rastogi et al., 1981). 
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Figure 1.3 Structure of the cell wall of mycobacteria (Source: http://www.ncbi.nlm.nih.gov/books/NBK1945/, 2011)  
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Permeability: In an earlier review by Minnikin (1982), it was proposed that mycolic 
acids in the outer cell wall layer were packed side by side in a perpendicular 
direction to the plane of the surface. It was also suggested that this mycolic acid-
containing layer was covered by an outer leaflet, composed of extractable lipids 
(exclusively of lipopolysacharides) and an inner leaflet, composed of phospolipids. 
Hence, the whole structure produced an asymmetric lipid bilayer (Minnikin, 1982). It 
is expected that the inner leaflet to have very low fluidity and mobility that 
contribute to less permeable outer bilayer membrane (Plésiat and Nikaido, 1992, 
Yuan et al., 1997, Liu et al., 1999). This assumption was supported by previous 
findings of Rastogi et al. (1990) that drug susceptibility of mycobacterium can be 
enhanced by inhibitors of cell envelope synthesis such as m-flourophenylalanine (an 
inhibitor of mycoside-C biosynthesis) and ethambutol (an inhibitor of 
arabinogalactan). On the basis of this justification several studies (Jarlier and 
Nikaido, 1994, Faller et al., 2004) suggested that the lipid domain of cell wall apt to 
be the source of impermeability in mycobacteria as this could act as an effective 
barrier for penetration of anti-mycobacterial agents.  
 In 1987, David et al. showed that lipophilic drugs such as ansamycin, 
rifampicin, clofazimine, and pristinamycin were active against M. avium strain 
tested. In subsequent studies by Rastogi et al. (1988) and Rastogi and Goh (1990), it 
was also shown that amphipathic INH derivatives have better efficacy against         
M. avium than the parent hydrophilic compound, INH. They surmised that these 
derivatives possibly increased the miscibility or liposolubility of the drugs in the 
lipid outer layer and interact with the amphipathic substance of the outer layer. Thus, 
this enables the drugs to easily penetrate through the cell wall to make it active 
against bacteria. In a recent study, Mohamad et al. (2004) also reported that a 
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lipophilic derivative of INH, 1-isonicotinyl-2-nonanoyl hydrazine (INH-C9) had a 
lower MIC value compared to INH. A similar positive correlation between 
lipophilicity and the anti-mycobacterial activity was also found among other classes 
of drug. For instance, Heifets et al. (1990) demonstrated that more hydrophobic 
derivatives of rifamycins, such as rifabutin, rifapentine, CGP-7040, KRM-1648, and 
T9 have enhanced activity against M. avium and M. tuberculosis. In addition, 
Franzblau and White (1990) findings also showed that more hydrophobic 
flouroquinolones were active against Mycobacterium leprae.  
On the basis of these antecedents, it is very obvious that the diffusion of 
lipophilic compounds occurs mainly through the lipid bilayer domains of the outer 
cell wall layer by solubilised in the amphipathic outer layer. Furthermore, Liu et al. 
(1999) explained that the penetration rate of hydrophobic compounds also depends 
on the two factors: (1) the compounds should have positive correlation with either 
theirol/water or octanol/water partition coefficients, and (2) high temperature 
coefficient because the fluidity of the lipid interior is temperature dependent.  
On the other hand, the hydrophilic molecules diffused into the bacteria via the 
protein channels known as porin (Niederweis, 2003). Jarlier and Nikaido (1990) 
showed that small hydrophilic nutrient molecules (such as glucose, glycerol, glycine, 
and leucine) diffuse through the porin channels. They also demonstrated that these 
porins were neither dependent on the hydrophobicity of the molecules nor the 
temperature. This again strongly suggests the hydrophilic pathway via porins for 
permeation of hydrophilic molecules. This observation ascertained by          
Kartmann et al. (1999) who showed that M. tuberculosis contains two types of porins 
which is a 15-kiloDalton (kDa) cation-selective that has short-lived open state and a 
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more than 60-kDa long-lived open state, which is mimicking the porins from        
fast-growing mycobacteria.  
 
1.3.6 Antimicrobial susceptibility testing 
The diagnosis and the performance of in vitro susceptibility tests against 
clinically significant M. tuberculosis endow essential information for effective TB 
treatment. It also allows early detection of drug resistant TB cases that lead to an 
initiation of appropriate treatment and surveillance of drug resistance (Martin and 
Portaels, 2007). In the past, these tests were known as conventional methods. 
Basically, the conventional methods are laborious and require longer duration to 
obtain the results. The current drastic development of new technologies and reagents 
had led to development of various simple and short turnaround time testing methods 
including phenotypic and genotypic methods.    
 
Conventional methods 
The proportion method is a golden standard method in studying the susceptibility 
of M. tuberculosis. Several dilutions of standard bacterial suspension were inoculated 
on the drug-containing and drug-free (control) plates and incubated. The colonies in 
both set of plates were then enumerated and proportion of resistance is calculated 
(Martin and Portaels, 2007). Usually, a strain is considered resistant if the proportion 
of resistance is higher than 1 %. This method is relatively very simple and cheap, yet 
cumbersome because it requires longer incubation period (3 - 4 weeks) to obtain the 
results (Varma et al., 2002). 
The Absolute concentration method is conducted via inoculating microorganism at 
2 x 10
3
 to 1 x 10
4
 colony forming unit (CFU) into media incorporated with and 
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without antimicrobial agents. The interpretation of the test is performed after at least 
4 weeks of incubation. A strain is categorized as resistant if there is greater than a 
certain number of CFU at a particular concentration (usually around 20 CFU) 
(Inderlied, 1991, Martin and Portaels, 2007).  
The resistant ratio method is quite similar to absolute concentration method except 
that another set of tubes are inoculated with a standard M. tuberculosis H37Rv strain 
and the results are interpreted in terms of the ratio of the MIC of drug against tested 
M. tuberculosis strain to the standard M. tuberculosis H37Rv (Inderlied, 1991). An 
isolate considered susceptible if the resistance ratio value 2 or less, while a resistance 
ratio of 8 or more defines the isolate as resistant (Martin and Portaels, 2007). 
The radiometric method is also known as BACTEC Method. This method is based 
on the ability of mycobacteria to catabolize radioactively labeled 
14
C fatty acids to 
carbon dioxide end product that can be detected and quantified by radiorespirometric 
method (Middlebrook et al., 1977). The major advantage of this method is the 
capacity to detect drug resistance faster (an average ranged from 4.2 to 6.9 days) 
compared to other conventional methods (Roberts et al., 1983). However, it requires 
expensive apparatus set up and proper radioactive waste disposal (Martin and 
Portaels, 2007). 
The mycobacterial growth indicator tube (MGIT). It is performed on the basis of 
fluorescence detection where Middlebrook 7H9 broth with an oxygen        
quenching-based fluorescent sensor is used. The growth of organism in the medium 
will cause the fluorescent dye to illuminate under UV light. This method is shown to 
be rapid (average 9.9 days), easy to handle and does not require additional costly 
instrumentation (Pfyffer et al., 1997, Somoskovi and Magyar, 1999).   
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Genotypic methods 
Desoxyribonucleic acid (DNA) sequencing is based on sequencing the gene 
responsible for certain trait and then comparing the sequence with the reference gene 
sequence to detect the mutation that gives resistance. Even though this is a rapid 
method, it cannot be conducted routinely because it is labor intensive and expensive 
(Hazbon, 2004).  
Solid-phase hybridization techniques is based on reverse hybridization of 
amplified DNA from culture and immobilized on a nitrocellulose or DNA strip and 
then, the presence of mutation can be visualized by colorimetric reaction in the form 
of band/s on the strip (De Beenhouwer et al., 1995, Makinen et al., 2006). This is a 
very rapid method because it does not require the growth of microorganism. The test 
can be performed directly on the sputum or biopsy samples (De Beenhouwer et al., 
1995). 
Real time Polymerase Chain Reaction (PCR) techniques. In this method the 
susceptibility of a strain is detected in regarding to gene mutation with the aid of 
probes such as TaqMan probe, Fluorescence Resonance Energy Transfer probes, 
molecular beacons and biprobes (Shamputa et al., 2004).  The foremost advantages 
of this method are the rapidity of the test and lower risk of contamination. Yet, it 
requires highly skilled personnel and expensive reagents and equipment making this 
technique not feasible in most laboratories and hospitals (Martin and Portaels, 2007). 
Microarrays are based on hybridization of DNA (from samples) to biochips with 
oligonucleotides immobilized on a solid support such as polyacrylamide gel pads 
(Gryadunov et al., 2005). As with other genotypic methods, this technique is also not 
feasible in most clinical mycobacteriology lab especially in third-world countries as 
it involves high cost and technology (Martin and Portaels, 2007). 
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Phenotypic methods 
The nitrate reductase assay is based on the ability of viable M. tuberculosis to 
reduce nitrate to nitrite in the medium with aid of a chemical reagent. Firstly, the 
cells will be exposed to a medium incorporated with chemical reagent and antibiotic 
at a specific concentration for 10 days. The resistant cells that reduce the nitrate 
cause a pink-red colour to be observed in the medium. The susceptible cells on the 
other hand will be inhibited where by the colour change will not be observed 
(Angeby et al., 2002).  
Colorimetric methods. The determination of susceptibility is based on the reduction 
of redox indicators or tetrazolium salts such as alamar blue or tetrazolium salt. The 
cells will be incubated with drugs in vitro in a range of concentration and then 
followed by the addition of an indicator. The resistant cells will cause the color 
change of the indicator. On the other hand, the susceptible cells will be inhibited and 
produce no colour change. The advantages of this method are that it is cheap,         
high-throughput, rapid, and feasible in any microbiology lab since it does not require 
any expensive apparatus. 
Phage-replication technology. This method is performed with the aid of 
mycobacteriophage, a lytic virus that is able to infect mycobacteria including          
M. tuberculosis and Mycobacterium smegmatis. Basically, the susceptibility is 
determined via the formation of clear zones known as plaques by the phage infected 
tubercle cells within the bacterial lawn. This simple test also can be used for the 
diagnosis of TB (McNerney, 2001).  
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1.3.7 Transmission and pathogenesis 
TB is an air borne disease. The predominant route of transmission of TB is by 
the small airborne droplets known as droplet nuclei, created through coughing, 
sneezing, talking, or singing by an untreated person suffering from pulmonary or 
laryngeal TB. It can also be generated by aerosol treatments, sputum induction, 
aerosolization during bronchoscopy, and by manipulation of lesions or processing of 
tissues or secretions in the hospital or laboratory (American Thoracic Society, 2000). 
These infected droplets can also remain in any indoor space for minute to hours 
(Knechel, 2009). 
Once inhaled, these droplet nuclei are very small enough to reach the alveoli 
of the lungs where the microorganisms replicate (American Thoracic Society, 2000). 
This will develop into infection of the respiratory system known as pulmonary TB. 
The M. tuberculosis cells are also able to spread to other organs such as lymphatics, 
pleura, bone or joints, or meninges and cause extrapulmonary TB (Knechel, 2009).  
With regard to pathogenicity, M. tuberculosis has shown to infect a variety of 
immunological cell populations such as macrophages, neutrophil leukocytes, mast 
cells, dentritic cells, and natural killer cells. Within them, macrophages especially 
alveolar macrophages are considered as the most important target of M. tuberculosis 
infection (Hernandez-Pando et al., 2007). Hence, the paradigmatic interaction during 
this infection is briefly discussed in this section.  
Once the tubercle bacilli in droplet nuclei reached the alveoli, it is quickly 
surrounded and engulfed by alveolar macrophages (McDonough et al., 1993). 
Following that, M. tuberculosis resides in the phagosome as an endocytic vacuole 
(Armstrong and Hart, 1975, Smith, 2003, Warner and Mizrahi, 2007).      
Phagosome-lysosome fusion will then take place where the cells within the 
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macrophages will be disclosed to multiple microbicidal mechanisms such as 
production of both reactive oxygen and nitrogen species, acidic pH, lysosomal 
enzymes, and toxic peptides to kill or inhibit the growth of mycobacteria (Smith, 
2003, Schluger, 2005). If the bacillus is able to survive these initial attacks, it will 
further multiply within the alveolar macrophages (American Thoracic Society, 2000, 
Knechal, 2009). At the same time, macrophages also initiate the production of 
proteolytic enzymes and cytokines as a further attempt to degrade these pathogenic 
microorganisms. The release of cytokines consequently attracts T lymphocytes to the 
infected site. This is done by the presentation of M. tuberculosis antigens on the 
surface of macrophages for recognition of T lymphocyte cells (Knechel, 2009). This 
initial mediated immune response prolongs for 2 to 12 weeks. During this time the 
tubercle cells also continuously grow until they reach 10
3
 to 10
4 
in number which is 
sufficient to elicit cell-mediated immune response (American Thoracic Society, 
2000, Knechel, 2009).  
In persons with intact cell-mediated immunity, the next defensive step is the 
formation of granulomas around the M. tuberculosis cells (Segovia-Juarez et al., 
2004, Schluger, 2005). These granulomas are formed through accumulation of 
activated T lymphocyte cells and macrophages, which creates a microenvironment 
that limits the further replication and spread of tubercle cells (American Thoracic 
Society, 2000, Knechel, 2009). This environment causes destruction of macrophages 
by apoptosis and produces early solid necrosis at the center of the lesion (Schluger, 
2005). However, some M. tuberculosis cells are still able to adapt this environment 
by mobilization of repair or detoxification pathway, or through changing the 
phenotypic pathways such as protein regulation to enhance their survival (Warner 
and Mizrahi, 2007). Within two to three weeks time the necrotic quiescence forms a 
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caseous necrosis with low oxygen level, low pH, and limited nutrient. Thus, this 
condition limits the growth of bacteria and leads to latency. These lesions might also 
undergo fibrosis and calcification which controls the tubercle bacilli in a dormant 
condition (Knechel, 2009). This condition is called latent TB where the disease is not 
active and infectious thus cannot be transmitted (Jasmer et al., 2002). However, 
certain diseases could lead to reactivation of these dormant cells such as silicosis, 
diabetes mellitus and disease associated with immunosuppressant (e.g. HIV 
infection) as well as through consumption of immunosuppressive drugs such as 
corticosteroid (American Thoracic Society, 2000, WHO, 2011a).  
On the other hand, in a weaker immune system person the granuloma 
formation fails to trap or contain the bacteria and this causes the necrotic cells to 
undergo liquefaction. Thus, the bacilli are able to escape and spread to other alveoli 
and other organs which eventually, will lead to primary progressive TB (Knechel, 
2009).   
 
1.3.8 Clinical manifestation (Symptoms and signs) 
The pulmonary system is the most common infection site of TB (known as 
pulmonary TB) involving lung parenchyma. It mainly occurs through the aerosol 
route and the symptoms are persisting cough, chest pain, sputum production, fever, 
night sweats, and hemoptysis (blood stained sputum) in severe conditions (Saviola 
and Bishai, 2006). Other signs of pulmonary TB include loss of appetite and weight, 
dyspnoea (difficulty in breathing), chest pain, and hoarseness of voice as well as 
abnormalities in the chest x-ray (Ministry of Health Malaysia, 2002). 
Extrapulmonary TB is tubercle infection that occurs outside the lungs 
(Davies, 2011). The risk of extrapulmonary TB is very high among immune 
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suppressed individuals especially patients with HIV infection and also among 
immunocompromised individuals such as in very young or old individuals (Saviola 
and Bishai, 2006). The main reason for this scenario is the failure of their immune 
response to contain tubercle cells which enables hematogenous dissemination and 
consequently leads to involvement of single or multiple non-pulmonary sites of 
infection (American Thoracic Society, 2000). There are only about 15 % probability 
of extrapulmonary TB in immunocompetent person and it is also attributed to 
reactivation from latent extrapulmonary (Saviola and Bishai, 2006, Knechel, 2009).  
One of the prominent constraints of extrapulmonary TB is the diagnosis. This 
is because it involves rarely accessible sites of infection and small numbers of bacilli 
which makes diagnosis difficult (American Thoracic Society, 2000). The systemic 
symptoms of extrapulmonary TB are often non-specific, including lassitude, 
anorexia, fever, and drastic weight loss (Ministry of Health Malaysia, 2002). 
Usually, the specific feature of extrapulmonary disease depends on the organs 
involved. The commonest sites of infection and its clinical manifestations are 
summarized as follows: 
1) Disseminated TB or military TB is considered as a most fatal form of 
extrapulmonary TB due to the infection in the blood (Knechel, 2009). Hence, the 
bacilli will spread throughout the body as the infected blood goes and lead to multi 
organ infection (Wang et al., 2007). The diagnosis of disseminated TB is also very 
complicated because the clinical manifestations are very confounding and 
nonspecific. Common symptoms would be fever, night sweats, abdominal pain, 
cough, weight loss, and aneroxia. The conditions of the organs involved are 
hepatomegaly, lymphadenopathy, and draining sinuses (Andres and Tan-Alora, 
2001).   
